Spots Global Cancer Trial Database for Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer

Official Title: Clinical Efficacy And Biologic Effects Of Preoperative Portal Vein Embolization In Patients With Colorectal Liver Metastases

Study ID: NCT00028626

Conditions

Colorectal Cancer

Metastatic Cancer

Interventions

embolization therapy

Study Description

Brief Summary: RATIONALE: Embolization blocks blood flow to part of an organ and/or tumor. Blocking the portal vein on one side of the liver may cause the opposite side of the liver to increase in size and decrease the risk of liver failure following surgery. PURPOSE: Phase II trial to study the effectiveness of portal vein embolization in treating patients who have liver metastases from primary colorectal cancer.

Detailed Description: OBJECTIVES: * Determine whether portal vein embolization results in significant hypertrophy of the remaining liver and potentially decreases the risk of liver failure after hepatic resection in patients with liver metastases from primary colorectal cancer. * Determine the biologic effects of this therapy on liver metastases and normal liver parenchyma in these patients. OUTLINE: Patients undergo portal vein embolization with 200-300 micron polyvinyl chloride particles suspended in Iohexol 300. Approximately 3-6 weeks after embolization, patients undergo an exploratory laparotomy followed by hepatic surgical resection. Patients are followed for at least 6 months. PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.